Summary & Overview
CPT 80349: Natural Cannabinoid Detection in Patient Specimen
CPT code 80349 represents laboratory testing to measure or detect the presence of natural cannabinoids in a patient specimen. As a laboratory toxicology assay, this code supports clinical care, forensic evaluations, workplace testing, and monitoring of substance exposure or use. Nationally, accurate coding for cannabinoid testing affects claims adjudication, coverage determinations, and interoperability of diagnostic reporting.
Key payers covered in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for cannabinoid testing, benchmarking of how this service is billed across major payers, and relevant policy considerations that influence coverage and payment. The publication outlines typical settings where the test is performed and summarizes what to expect in claims processing for this laboratory service.
This summary provides clinicians, billing professionals, and policy analysts with the essential facts about CPT code 80349, including its clinical purpose, common use cases, and payer landscape. Data not available in the input is noted where specific benchmarking or code correlation details are absent.
Billing Code Overview
CPT code 80349 describes a laboratory test in which the analyst measures the amount of or detects the presence of natural cannabinoids in a patient specimen. This service is a toxicology and substance detection assay focused on naturally occurring cannabinoids such as those derived from cannabis plants.
-
Service type: Laboratory diagnostic testing for natural cannabinoid detection
-
Typical site of service: Clinical laboratory or hospital laboratory processing patient specimens
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 28-year-old patient presents to an outpatient addiction medicine clinic for evaluation after workplace concern for cannabis use. The clinician orders a urine drug test to detect and quantify naturally occurring cannabinoids in the specimen to determine recent cannabis exposure and support clinical counseling. The specimen is collected in the clinic or sent from a collection site to the clinical laboratory. In the laboratory, a medical technologist or lab analyst performs qualitative screening and quantitative confirmation of natural cannabinoids (e.g., THC, 11-nor-9-carboxy-THC) using validated methods such as immunoassay screening followed by gas chromatography–mass spectrometry (GC-MS) or liquid chromatography–tandem mass spectrometry (LC-MS/MS). Results are reported to the ordering provider and incorporated into the patient’s chart for treatment planning, occupational clearance decisions, or medico-legal documentation. Typical documentation includes the specimen type, collection time, analytic method, analytes tested, and numeric concentrations when quantitative testing is performed. Typical turnaround time ranges from same-day to 48 hours depending on onsite capability and confirmatory testing workflow.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the professional interpretation component of the test separate from the technical laboratory work. |